Abstract:1. In AML, two SE‐related transcripts IGF2BP2 and IGF2BP3 were identified, whose activation could be triggered by SE machinery. 2. IGF2BP2 and IGF2BP3 strengthened the stability of DDX21 mRNA in an m6 A‐dependent manner. 3. Knockdown of DDX21 inhibited proliferation, promoted apoptosis and led to cell cycle arrest in AML cells. 4. DDX21 recruited transcription factor YBX1 to cooperatively facilitate the transcription of ULK1. Background Acute myeloid leukaemia (AML) is a haematological malignancy with unfavourable prognosis. Despite the effectiveness of chemotherapy and targeted therapy, relapse or drug resistance remains a major threat to AML patients. N6‐methyladenosine (m6A) RNA methylation and super‐enhancers (SEs) are extensively involved in the leukaemogenesis of AML. However, the potential relationship between m6A and SEs in AML has not been elaborated. Methods Chromatin immunoprecipitation (ChIP) sequencing data from Gene Expression Omnibus (GEO) cohort were analysed to search SE‐related genes. The mechanisms of m6 A‐binding proteins IGF2BP2 and IGF2BP3 on DDX21 were explored via methylated RNA immunoprecipitation (MeRIP) assays, RNA immunoprecipitation (RIP) assays and luciferase reporter assays. Then we elucidated the roles of DDX21 in AML through functional assays in vitro and in vivo. Finally, co‐immunoprecipitation (Co‐IP) assays, RNA sequencing and ChIP assays were performed to investigate the downstream mechanisms of DDX21. Results We identified two SE‐associated transcripts IGF2BP2 and IGF2BP3 in AML. High enrichment of H3K27ac, H3K4me1 and BRD4 was observed in IGF2BP2 and IGF2BP3, whose expression were driven by SE machinery. Then IGF2BP2 and IGF2BP3 enhanced the stability of DDX21 mRNA in an m6A‐dependent manner. DDX21 was highly expressed in AML patients, which indicated a poor survival. Functionally, knockdown of DDX21 inhibited cell proliferation, promoted cell apoptosis and led to cell cycle arrest. Mechanistically, DDX21 recruited transcription factor YBX1 to cooperatively trigger ULK1 expression. Moreover, silencing of ULK1 could reverse the promoting effects of DDX21 overexpression in AML cells. Conclusions Dysregulation of SE‐IGF2BP2/IGF2BP3‐DDX21 axis facilitated the progression of AML. Our findings provide new insights into the link between SEs and m6A modification, elucidate the regulatory mechanisms of IGF2BP2 and IGF2BP3 on DDX21, and reveal the underlying roles of DDX21 in AML.

RNA N6-methyladenosine Reader IGF2BP3 Promotes Acute Myeloid Leukemia Progression by Controlling Stabilization of EPOR Mrna.

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

IGF2BP3 As an N6-Methyladenosine Reader Promotes Acute Myeloid Leukemia Progression by Regulating the Stability of Target RNA

The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner

Metabolic regulation of RNA methylation by the m6A-reader IGF2BP3

Characterization of m6A regulator‐mediated methylation modification patterns and tumor microenvironment infiltration in acute myeloid leukemia

Super-Enhancer-Driven IGF2BP2 and IGF2BP3 Promote DDX21 Expression in Acute Myeloid Leukemia

Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia

The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia

EGR2-mediated regulation of m6A reader IGF2BP proteins drive RCC tumorigenesis and metastasis via enhancing S1PR3 mRNA stabilization

RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma

m6A regulator-based methylation modification patterns and characterization of tumor microenvironment in acute myeloid leukemia

Dysregulation of N-6-methyladenosine Regulators Predicts Poor Patient Survival in Mantle Cell Lymphoma

m6A‐dependent upregulation of DDX21 by super‐enhancer‐driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia

An Oncopeptide Regulates M(6)A Recognition By The M(6)A Reader Igf2bp1 And Tumorigenesis

Physio-pathological Effects of N6-methyladenosine and Its Therapeutic Implications in Leukemia

The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients

Reprogramming of RNA m6A Modification Is Required for Acute Myeloid Leukemia Development

DMDRMR-Mediated Regulation of M6a-Modified CDK4 by M6a Reader IGF2BP3 Drives Ccrcc Progression.